ONC002

ONC002 is a preclinical-stage bispecific antibody (BsAb) being developed by OncoPrecision. It is designed to target and modulate tumor-associated macrophages (TAMs) for potential applications in immunity and inflammation. The drug is discovered using OncoPrecision's proprietary platform, which integrates patient-derived high-throughput biology with AI/ML to identify novel therapeutic targets. As of early 2024, the specific molecular targets of ONC002 remain undisclosed, and the program is in the target validation phase of development. The therapeutic intent is to reprogram or modulate the immunosuppressive environment created by macrophages in tumors or inflammatory conditions.